Mohammad Iqbal H Bhuiyan1,2,3, Cullen B Young1,2, Israt Jahan1,2, Md Nabiul Hasan1,2, Sydney Fischer1,2, Nur Farah Meor Azlan4, Mingjun Liu5, Ansuman Chattopadhyay6, Huachen Huang1, Kristopher T Kahle7, Jinwei Zhang4, Samuel M Poloyac8, Bradley J Molyneaux1,2, Adam C Straub9,10, Xianming Deng11, Delphine Gomez5,10, Dandan Sun1,2,3. 1. Departments of Neurology (M.I.H.B., C.B.Y., I.J., M.N.H., S.F., H.H., B.J.M., D.S.), University of Pittsburgh, PA. 2. Pittsburgh Institute for Neurodegenerative Disorders (M.I.H.B., C.B.Y., I.J., M.N.H., S.F., B.J.M., D.S.), University of Pittsburgh, PA. 3. Veterans Affairs Pittsburgh Health Care System, Geriatric Research, Educational, and Clinical Center, PA (M.I.H.B.' D.S.). 4. Institute of Biomedical and Clinical Sciences, University of Exeter Medical School, Exeter, United Kingdom (N.F.M.A., J.Z.). 5. Medicine (M.L., D.G.), University of Pittsburgh, PA. 6. Molecular Biology-Information Service, Health Sciences Library System (A.C.), University of Pittsburgh, PA. 7. Department of Neurosurgery, Massachusetts General Hospital and Harvard Medical School, Boston (K.T.K.). 8. College of Pharmacy, University of Texas, Austin (S.M.P). 9. Pharmacology and Chemical Biology (A.C.S), University of Pittsburgh, PA. 10. Pittsburgh Heart, Lung, Blood, and Vascular Medicine Institute (A.C.S., D.G.), University of Pittsburgh, PA. 11. State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Xiamen University, Fujian, China (X.D.).
Abstract
BACKGROUND: Worsened stroke outcomes with hypertension comorbidity are insensitive to blood pressure-lowering therapies. In an experimental stroke model with comorbid hypertension, we investigated causal roles of ang II (angiotensin II)-mediated stimulation of the brain WNK (with no lysine [K] kinases)-SPAK (STE20/SPS1-related proline/alanine-rich kinase)-NKCC1 (Na-K-Cl cotransporter) complex in worsened outcomes. METHODS: Saline- or ang II-infused C57BL/6J male mice underwent stroke induced by permanent occlusion of the distal branches of the middle cerebral artery. Mice were randomly assigned to receive either vehicle dimethyl sulfoxide/PBS (2 mL/kg body weight/day, IP), a novel SPAK inhibitor, 5-chloro-N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)-2-hydroxybenzamide (ZT-1a' 5 mg/kg per day, IP) or a NF-κB (nuclear factor-κB) inhibitor TAT-NBD (transactivator of transcription-NEMO-binding domain' 20 mg/kg per day, IP). Activation of brain NF-κB and WNK-SPAK-NKCC1 cascade as well as ischemic stroke outcomes were examined. RESULTS: Stroke triggered a 2- to 5-fold increase of WNK (isoforms 1, 2, 4), SPAK/OSR1 (oxidative stress-responsive kinase 1), and NKCC1 protein in the ang II-infused hypertensive mouse brains at 24 hours after stroke, which was associated with increased nuclear translocation of phospho-NF-κB protein in the cortical neurons (a Pearson correlation r of 0.77, P<0.005). The upregulation of WNK-SPAK-NKCC1 cascade proteins resulted from increased NF-κB recruitment on Wnk1, Wnk2, Wnk4, Spak, and Nkcc1 gene promoters and was attenuated by NF-κB inhibitor TAT-NBD. Poststroke administration of SPAK inhibitor ZT-1a significantly reduced WNK-SPAK-NKCC1 complex activation, brain lesion size, and neurological function deficits in the ang II-hypertensive mice without affecting blood pressure and cerebral blood flow. CONCLUSIONS: The ang II-induced stimulation of NF-κB transcriptional activity upregulates brain WNK-SPAK-NKCC1 cascade and contributes to worsened ischemic stroke outcomes, illustrating the brain WNK-SPAK-NKCC1 complex as a therapeutic target for stroke with comorbid hypertension.
BACKGROUND: Worsened stroke outcomes with hypertension comorbidity are insensitive to blood pressure-lowering therapies. In an experimental stroke model with comorbid hypertension, we investigated causal roles of ang II (angiotensin II)-mediated stimulation of the brain WNK (with no lysine [K] kinases)-SPAK (STE20/SPS1-related proline/alanine-rich kinase)-NKCC1 (Na-K-Cl cotransporter) complex in worsened outcomes. METHODS: Saline- or ang II-infused C57BL/6J male mice underwent stroke induced by permanent occlusion of the distal branches of the middle cerebral artery. Mice were randomly assigned to receive either vehicle dimethyl sulfoxide/PBS (2 mL/kg body weight/day, IP), a novel SPAK inhibitor, 5-chloro-N-(5-chloro-4-((4-chlorophenyl)(cyano)methyl)-2-methylphenyl)-2-hydroxybenzamide (ZT-1a' 5 mg/kg per day, IP) or a NF-κB (nuclear factor-κB) inhibitor TAT-NBD (transactivator of transcription-NEMO-binding domain' 20 mg/kg per day, IP). Activation of brain NF-κB and WNK-SPAK-NKCC1 cascade as well as ischemic stroke outcomes were examined. RESULTS: Stroke triggered a 2- to 5-fold increase of WNK (isoforms 1, 2, 4), SPAK/OSR1 (oxidative stress-responsive kinase 1), and NKCC1 protein in the ang II-infused hypertensive mouse brains at 24 hours after stroke, which was associated with increased nuclear translocation of phospho-NF-κB protein in the cortical neurons (a Pearson correlation r of 0.77, P<0.005). The upregulation of WNK-SPAK-NKCC1 cascade proteins resulted from increased NF-κB recruitment on Wnk1, Wnk2, Wnk4, Spak, and Nkcc1 gene promoters and was attenuated by NF-κB inhibitor TAT-NBD. Poststroke administration of SPAK inhibitor ZT-1a significantly reduced WNK-SPAK-NKCC1 complex activation, brain lesion size, and neurological function deficits in the ang II-hypertensive mice without affecting blood pressure and cerebral blood flow. CONCLUSIONS: The ang II-induced stimulation of NF-κB transcriptional activity upregulates brain WNK-SPAK-NKCC1 cascade and contributes to worsened ischemic stroke outcomes, illustrating the brain WNK-SPAK-NKCC1 complex as a therapeutic target for stroke with comorbid hypertension.
Authors: Kerstin Römermann; Maren Fedrowitz; Philip Hampel; Edith Kaczmarek; Kathrin Töllner; Thomas Erker; Douglas H Sweet; Wolfgang Löscher Journal: Neuropharmacology Date: 2017-02-10 Impact factor: 5.250
Authors: Masoud Shekarabi; Jinwei Zhang; Arjun R Khanna; David H Ellison; Eric Delpire; Kristopher T Kahle Journal: Cell Metab Date: 2017-02-07 Impact factor: 27.287
Authors: Juraj Culman; Toni Jacob; Sven O Schuster; Kjell Brolund-Spaether; Leonie Brolund; Ingolf Cascorbi; Yi Zhao; Peter Gohlke Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2017-07-02 Impact factor: 3.000
Authors: Leon P Munting; Marc P P Derieppe; Ernst Suidgeest; Baudouin Denis de Senneville; Jack A Wells; Louise van der Weerd Journal: NMR Biomed Date: 2019-06-07 Impact factor: 4.044
Authors: Jinwei Zhang; Mohammad Iqbal H Bhuiyan; Ting Zhang; Jason K Karimy; Zhijuan Wu; Victoria M Fiesler; Jingfang Zhang; Huachen Huang; Md Nabiul Hasan; Anna E Skrzypiec; Mariusz Mucha; Daniel Duran; Wei Huang; Robert Pawlak; Lesley M Foley; T Kevin Hitchens; Margaret B Minnigh; Samuel M Poloyac; Seth L Alper; Bradley J Molyneaux; Andrew J Trevelyan; Kristopher T Kahle; Dandan Sun; Xianming Deng Journal: Nat Commun Date: 2020-01-07 Impact factor: 14.919
Authors: Jinwei Zhang; Geng Gao; Gulnaz Begum; Jinhua Wang; Arjun R Khanna; Boris E Shmukler; Gerrit M Daubner; Paola de Los Heros; Paul Davies; Joby Varghese; Mohammad Iqbal H Bhuiyan; Jinjing Duan; Jin Zhang; Daniel Duran; Seth L Alper; Dandan Sun; Stephen J Elledge; Dario R Alessi; Kristopher T Kahle Journal: Sci Rep Date: 2016-10-26 Impact factor: 4.996